How to buy Exopharm shares | A$0.34

Exopharm Limited is a biotechnology business based in Australia. Exopharm shares (EX1) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Its last market close was $0.34 – an increase of 13.33% over the previous week. Exopharm has a trailing 12-month revenue of around $2.7 million.

How to buy shares in Exopharm

1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
3. Search for Exopharm . Find the share by name or ticker symbol: EX1. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Exopharm reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At today's price of $0.34, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
6. Check in on your investment. Congratulations, you own a part of Exopharm . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

🧪How we chose these brokers

For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.

How has coronavirus impacted Exopharm 's share price?

Since the stock market crash in March caused by coronavirus, Exopharm 's share price has had significant positive movement.

Its last market close was $0.34, which is 8.82% up on its pre-crash value of $0.31 and 134.48% up on the lowest point reached during the March crash when the shares fell as low as $0.145.

If you had bought $1,000 worth of Exopharm shares at the start of February 2020, those shares would have been worth $517.86 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,214.29.

Exopharm share price

Use our graph to track the performance of EX1 stocks over time.

Exopharm shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	AUDA$0.34
52-week range	AUDA$0.145 - AUDA$0.405
50-day moving average	AUDA$0.3136
200-day moving average	AUDA$0.2624
Target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	AUDA$-0.04

Share Trading Account Offer

IG Share Trading Offer

AUD 8

Standard brokerage - Australian shares

Share Trading Account Offer

Competitive broker fees on Australian and international shares

• Brokerage - AU shares: From AUD 5 or 0.05%
• Brokerage - US shares: USD 0
• Sign-up process: Instant
• Support - After hours: Yes

Go to site

More info

Important: Share trading carries risk of capital loss.

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Exopharm stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Exopharm Limited by TradingView

Exopharm price performance over time

Historical closes compared with the close of A$0.34 on 2020-10-22

1 week (2020-10-21)	0%
1 month (2020-09-29)	4.62%
3 months (2020-07-28)	15.25%
6 months (2020-04-28)	78.95%

1 year (2019-10-28)	-10.53%
2 years (2018-10-25)	N/A
3 years (2017-10-25)	N/A
5 years (2015-10-25)	N/A

Exopharm financials

Revenue TTM	$2.7 million
Gross profit TTM	$-314,976
Return on assets TTM	-55.88%
Return on equity TTM	-104.15%
Profit margin	-198.04%
Book value	0.053
Market capitalisation	$37 million

TTM: trailing 12 months

Exopharm share dividends

We're not expecting Exopharm to pay a dividend over the next 12 months.

Exopharm overview

Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics using extracellular vesicles (EVs) as medicines in Australia. The company is developing Naïve EVs as regenerative medicines, including Plexaris for wound healing; and Cevaris used in inflammatory, immunomodulatory, and tissue remodeling activities. Its Engineered EVs products comprise Fortrexo CoV, an engineered EV product that reduce the duration and severity of SARS-CoV-2 infection in the early phase of a patient's exposure to COVID-19; and Plexodox, a platelet derived EV loaded with the approved anti-cancer drug doxorubicin as a novel and improved anticancer drug. The company was founded in 2013 and is headquartered in Melbourne, Australia.

Frequently asked questions

• What percentage of Exopharm is owned by insiders or institutions?

  Currently 47.219% of Exopharm shares are held by insiders and 0.848% by institutions.

• When does the fiscal year end for Exopharm ?

  Exopharm 's fiscal year ends in June.

• Where is Exopharm based?

  Exopharm 's address is: 31 Queen Street, Melbourne, VIC, Australia, 3000